↓ Skip to main content

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma

Overview of attention for article published in Annals of Oncology, March 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news
2 news outlets
twitter
51 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
85 Dimensions

Readers on

mendeley
131 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma
Published in
Annals of Oncology, March 2018
DOI 10.1093/annonc/mdx765
Pubmed ID
Authors

A.K. Krug, D. Enderle, C. Karlovich, T. Priewasser, S. Bentink, A. Spiel, K. Brinkmann, J. Emenegger, D.G. Grimm, E. Castellanos-Rizaldos, J.W. Goldman, L.V. Sequist, J.-C. Soria, D.R. Camidge, S.M. Gadgeel, H.A. Wakelee, M. Raponi, M. Noerholm, J. Skog

Abstract

A major limitation of circulating tumor DNA (ctDNA) for somatic mutation detection has been the low level of ctDNA found in a subset of cancer patients. We investigated whether using a combined isolation of exosomal RNA (exoRNA) and cell-free DNA (cfDNA) could improve blood-based liquid biopsy for EGFR mutation detection in NSCLC patients. Matched pretreatment tumor and plasma were collected from 84 patients enrolled in TIGER-X (NCT01526928), a Ph1/2 study of rociletinib in mutant EGFR NSCLC patients. The combined isolated exoRNA and cfDNA (exoNA) was analyzed for mutations using a targeted NGS panel (EXO1000), and compared to existing data from the same samples using analysis of ctDNA by BEAMing. For exoNA, the sensitivity was 98% for detection of activating EGFR mutations and 90% for EGFR T790M. The corresponding sensitivities for ctDNA by BEAMing were 82% for activating mutations and 84% for T790M. In a subgroup of patients with intrathoracic metastatic disease (M0/M1a; n = 21), the sensitivity increased from 26% to 74% for activating mutations (p = 0.003) and from 19% to 31% for T790M (p = 0.5) when using exoNA for detection. Combining exoRNA and ctDNA increased the sensitivity for EGFR mutation detection in plasma, with the largest improvement seen in the subgroup of M0/M1a disease patients known to have low levels of ctDNA which poses challenges for ctDNA-only based mutation detection. NCT01526928.

Twitter Demographics

The data shown below were collected from the profiles of 51 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 131 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 131 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 25 19%
Student > Ph. D. Student 24 18%
Other 11 8%
Student > Master 11 8%
Student > Postgraduate 8 6%
Other 21 16%
Unknown 31 24%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 39 30%
Medicine and Dentistry 24 18%
Agricultural and Biological Sciences 16 12%
Engineering 6 5%
Pharmacology, Toxicology and Pharmaceutical Science 4 3%
Other 8 6%
Unknown 34 26%

Attention Score in Context

This research output has an Altmetric Attention Score of 47. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 May 2021.
All research outputs
#559,656
of 17,831,129 outputs
Outputs from Annals of Oncology
#279
of 6,651 outputs
Outputs of similar age
#19,683
of 419,525 outputs
Outputs of similar age from Annals of Oncology
#13
of 167 outputs
Altmetric has tracked 17,831,129 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,651 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.5. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 419,525 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 167 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.